Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-09-02
2008-09-02
Huynh, Phuong (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C536S023530
Reexamination Certificate
active
11221203
ABSTRACT:
The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
REFERENCES:
patent: 5601821 (1997-02-01), Stanworth et al.
patent: 5629415 (1997-05-01), Hollis et al.
patent: 5653980 (1997-08-01), Hellman
patent: 6974572 (2005-12-01), Morsey et al.
patent: 0 236 655 (1988-04-01), None
patent: 594610 (1998-09-01), None
patent: 1 195 161 (2002-04-01), None
patent: WO 92/20316 (1992-11-01), None
patent: WO 92/22635 (1992-12-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/08598 (1994-04-01), None
patent: WO 95/26365 (1995-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/25722 (2000-05-01), None
patent: WO 00/50461 (2000-08-01), None
Verma et al., Nature 389: 239-242, Sep. 1997.
Nissim et al, EMBO J 10(1): 101-107, 1991.
Reyes-Sandoval et al, Curr Mol Med 1(2):217-43, May 2001.
Tuteja et al, Crit Rev Biochem Mol Biol 34(1):1-24, 1999.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
David S. Burt, et al., “Inhibition of Binding of Rat IgE to Rat Mast Cells by Synthetic IgE Peptides”,Eur. J. Immunol., 17:437-440, (1987).
Birgit Helm, et al., “The Mast Cell Binding Site on Human Immunoglobulin E”,Nature, 331:180-183, (1988).
Birgit Helm, et al., “Blocking of Passive Sensitization of Human Mast Cells and Basophil Granulocytes with IgE Antibodies by a Recombinant Human ε-chain Fragment of 76 Amino Acids”,Proc. Natl. Acad. Sci., 86:9465-9469, (1989).
Donata Vercelli, et al., “The B-Cell Binding Site on Human Immunoglobulin E”,Nature, 338:649-651, (1989).
Noriki Nio, et al., “Inhibition of Histamine Release by Synthetic Human IgE Peptide Fragments: Structure-Activity Studies”,Peptide Chemistry, 203-208, (1990).
Noriki Nio, et al., “Inhibition of Passive Sensitization of Human Peripheral Basophils by Synthetic Human Immunoglobulin E Peptide Fragments”,FEBS, 319(3):225-228, (1993).
Noriki Nio, et al., “Inhibition of Passive Cutaneous Anaphylaxis by Synthetic Human Immunoglobulin E Peptide Fragments”,FEBS, 314(3):229-231, (1992).
Mitali Basu, et al., “Purification and Characterization of Human Recombinant IgE-Fc Fragments that Bind to the Human High Affinity IgE Receptor”,The Journal of Biological Chemistry, 268(18):13118-13127, (1993).
Luca Vangelista, et al., “The Immunoglobulin-Like Modules Cε3 and α2 are the Minimal Units Necessary for Human IgE-FcεRI Interaction”,The Journal of Clinical Investigation, 103(11):1571-1578, (1999).
Michael W. Robertson, et al. “IgE Structure-Function Relationships Defined by Sequence Directed Antibodies Induced by Synthetic Peptides”,Molecular Immunology, 25(2):103-113 (1988).
Shelley Schwarzbaum, et al., “Mapping of Murine IgE Epitopes Involved in IgE-Fcε Receptor Interactions”,Eur. J. Immunol., 19:1015-1023, (1989).
Marla Weetall, et al., “Mapping the Site of Interaction Between Murine IgE and its High Affinity Receptor with Chimeric Ig1”,The Journal of Immunology, 145(11):3849-3854, (1990).
Leonard Presta, et al., “The Binding Site on Human Immunoglobulin E for its High Affinity Receptor”,The Journal of Biological Chemistry, 269(42):26368-26373, (1994).
Ahuva Nissim, et al., “Fine Specificity of the IgE Interaction with the Low and High Affinity Fc Receptor1”,The Journal of Immunology, 150(4):1365-1374, (1993).
Jaime Moscoso Del Prado, et al., “Monoclonal Antibodies Against Human IgE Identification of an Epitope Sharing Properties with the High-Affinity Receptor Binding Site”,Molecular Immunology, 28(8):839-844, (1991).
Achsah D. Keegan, et al., “Characterization of New Rat Anti-Mouse IgE Monoclonals and Their Use Along With Chimeric IgE to Further Define the Site that Interacts with FcεRII and FcεRI”,Molecular Immunology, 28(10):1149-1154, (1991).
William A. Hook, et al., “Monoclonal Antibodies Defining Epitopes on Human Ige”,Molecular Immunology, 28(6):631-639, (1991).
Hiroshi Takemoto, et al., “Anti-Human IgE Monoclonal Antibodies Recognizing Epitopes Related to the Binding Sites of High and Low Affinity IgE Receptors”,Microbiol. Immunol., 38(1):63-71, (1994).
Michal Baniyash, et al., “Anti-IgE Monoclonal Antibodies Directed at the Fcε Receptor Binding Site”,Molecular Immunology, 25(8):705-711, (1988).
Tse Wen Chang, “The Pharmacological Basis of Anti-IgE Therapy”,Nature Biotechnology, 18:157-162, (2000).
Leonard G. Presta, et al., “Humanization of an Antibody Directed Against IgE”,The Journal of Immunology, 151(5):2623-2632, (1993).
Beda M. Stadler, et al., “Biological Activities of Anti-IgE Antibodies”,Int Arch Allergy Immunol., 102:121-126, (1993).
Michael P. Rudolf, et al., “Epitope-Specific Antibody Response to IgE by Mimotope Immunization”,The Journal of Immunology, 160:3315-3321, (1998).
Barry R. Goldspiel, et al., “Human Gene Therapy”,Clinical Pharmacy, 12:488-505, (1993).
George Y. Wu, et al., “Delivery Systems for Gene Therapy”,Biotherapy, 3:87-95, (1991).
Paul Tolstoshev, “Gene Therapy, Concepts, Current Trials and Future Directions”,Annu. Rev Pharmacol. Toxicol., 32:573-596, (1993).
Richard C. Mulligan, “The Basic Science of Gene Therapy”,Science, 260:926-932, (1993).
Richard A. Morgan, et al., “Human Gene Therapy”,Annu. Rev. Biochem., 62:191-217, (1993).
Beverly H. Koller, et al., “Inactivating the β2-Microglobulin Locus in Mouse Embryonic Stem Cells by Homologous Recombination”,Proc. Natl. Acad. Sci., 86:8932-8935 (1989).
Maarten Zijlstra, et al., “Germ-line Transmission of a Disrupted β2-Microglobulin Gene Produced by Homologous Recombination in Embryonic Stem Cells”,Nature, 342:435-438, (1989).
George Y. Wu, et al., “Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System”,The Journal of Biological Chemistry, 262(10):4429-4432, (1987).
A. Dusty Miller, et al., “Use of Retroviral Vectors for Gene Transfer and Expression”,Methods in Enzymology, 217(76):581-599, (1990).
Monika M. Clowes, et al., “Long-Term Biological Response of Injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes”,J. Clin. Invest., 93:644-651, (1994).
Karen F. Kozarsky, et al., “Gene Therapy: Adenovirus Vectors”,Current Opinion in Genetics and Development, 3:499-503, (1993).
Christopher E. Walsh, et al., “Gene Therapy for Human Hemoglobinopathies”,P.S.E.B.M., 204:289-300, (1993).
Jean-Philippe Loeffler, et al., “Gene Transfer into Primary and Established Mammalian Cell Lines with Lipopolyamine-Coated DNA”,Methods in Enzymology, 217:599-619, (1993).
Derek L. Stemple, et al., “Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest”,Cell, 71:973-985, (1992).
James G. Rheinwald, “Serial Cultivation of Normal Human Epidermal Keratinocytes”,Methods in Cell Biology, 21A:229-254, (1980).
Mark R. Pittelkow, M.D., et al., “New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on their Use for Grafting of Patients with Extensive Burns”,Mayo Clinic Proceedings, 61:771-777, (1986).
Robert Langer, “New Methods of Drug Delive
Brown Tracy M.
Morsey Mohamad A.
Gumbleton Timothy J.
Huynh Phuong
Pfizer Inc.
Pfizer Products
LandOfFree
Non-anaphylactogenic IgE fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-anaphylactogenic IgE fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-anaphylactogenic IgE fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3906679